Definitions

Complicated UTI

All UTIs which are not defined as uncomplicated. Meaning, in a narrower sense, UTIs in a patient with an increased chance of a complicated course: i.e. all men, pregnant women, patients with relevant anatomical or functional abnormalities of the urinary tract, indwelling urinary catheters, renal diseases, and/or with other concomitant immunocompromising diseases for example poorly controlled diabetes.

Pyelonephritis

Pyelonephritis is an upper UTI and is suggested by fever (>38°C), chills, flank pain, nausea, vomiting, or costovertebral angle tenderness, with or without symptoms or cystitis.

Urosepsis

Urosepsis is defined as life threatening organ dysfunction caused by a dysregulated systemic host response to infection originating from the urinary tract and/or male genital organs.

Catheter-associated UTI (CAUTI)

CAUTI refers to UTIs occurring in a person whose urinary tract is currently catheterised or has had a catheter in place within the past 48 hours.

Uncomplicated UTI

Acute, sporadic or recurrent lower (uncomplicated cystitis) and/or upper (uncomplicated pyelonephritis) UTI, limited to non-pregnant women with no known relevant anatomical and functional abnormalities within the urinary tract or comorbidities.

Uncomplicated Cystitis

Acute, sporadic or recurrent lower UTI limited to non-pregnant women with no known relevant anatomical and functional abnormalities within the urinary tract or comorbidities. Recurrences of cystitis are most frequently found in women.

Recurrent UTI

The definition for rUTIs depends on expert opinion. EAU guidelines define rUTIs as recurrences of uncomplicated and/or complicated UTIs, with a frequency of at least three UTIs/year or two UTIs in the last six months. A recurrence is a new symptomatic UTI episode, whereas relapse is a recurrence with the same bacterial species and reinfection with a different bacterial species. RECAP

Additional Definitions

Antibiotic resistance

Antibiotic logo

The adaptation of bacteria in response to antibiotics, rendering the treatment ineffective. Antibiotic resistance is accelerated by the misuse and overuse of antibiotics, as well as poor infection prevention and control.

Antimicrobial stewardship

Antimicrobial stewardship logo

The aim to optimise clinical outcomes and ensure costeffective therapy, whilst minimising unintended consequences of antimicrobial use, such as healthcare associated infections (including Clostridium difficile), toxicity, selection of virulent organisms and emergence of resistant bacterial strains.

Asymptomatic bacteriuria (ABU)

Asymptomatic bacteriuria logo

ABU in an individual without urinary tract symptoms is defined by a mid-stream sample of urine showing bacterial growth a potency of 105
colony-forming units per millilitre (CFU/ml) in two consecutive samples in women and in one single sample in men.

Gut microbiota

Gut microbiota logo

The gut microbiome is the totality of microorganisms: bacteria, viruses, protozoa, and fungi, and their collective genetic material present in the gastrointestinal tract.

Natural reservoirs/ disease reservoirs

Disease reservoirs pathogen logo

One or more epidemiologically connected populations or environments in which the pathogen can be permanently maintained and from which infection is transmitted to the defined target population. The main disease reservoirs for urogenital infections are the vagina and the gut. Other bacterial reservoirs in urological infections are intracellular bacterial communities that shed themselves preventing full pathogenic bacteria clearance by the host first and second line defences.

Refractory

Refractory logo

Persistence of the same bacterial species during antimicrobial therapy. RECAP

Stress/urge urinary incontinence

Stress incontinence logo

Stress incontinence: involuntary leakage of urine from the bladder accompanying physical activity (such as laughing or coughing) which places increased pressure on the abdomen. Urge incontinence: involuntary leakage of urine from the bladder when a sudden strong need to urinate is felt.

Vaginal microbiota

Vaginal microbiota logo

The collection of microorganisms that reside in the vagina. Lactobacillus spp. are the dominant vaginal bacterial species in a majority of healthy women. In case this normal balance is disturbed and the proportion of Lactobacillus spp. is decreased the vagina may become a disease reservoir for urogenital infections. RECAP

Recurrent cystitis is the main focus of The REcurrent Cystitis Awareness Program RECAP.

ABBREVIATIONS
ABU
Asymptomatic bacteriuria | ACSS Acute Cystitis Symptom Score | AKI Acute Kidney Injury | AP Aminopenicillins | AUA American Urological Association | AUC Acute Uncomplicated Cystitis | CAUTI Catheter-associated UTI | CIHR Canadian Institute for Health Research | CRE Carbapenem-resistant Enterobacteriaceae | CUA Canadian Urological Association | cUTI complicated UTI | DGU German Society of Urology | DM Diabetes Mellitus | EAU European Association of Urology | ESBL Extended Spectrum Beta-Lactamases | ESCMID European Society for Clinical Microbiology and Infectious Diseases | ESIU European Section of Infection in Urology | IBCs Intracellular Bacterial Communities | ISAC International Society of Antimicrobial Chemotherapy | LATAM Latin America | MRSA Methicillin-resistant Staphylococcus aureus | QoL Quality of Life | RECAP The REcurrent Cystitis Awareness Program | rUC recurrent Uncomplicated Cystitis | rUTIs recurrent UTIs | SF-12v2 Health-related quality-of-life questionnaire | SMUG Sociedad Mexicana de Uroginecología | SMZ sulfamethoxazole | SUFU Society of Urodynamics, Female Pelvic Medicine and Urogenital reconstruction | UPEC Uropathogenic E. coli | US United States | UTI Urinary Tract Infection | VRE Vancomycin-resistant Enterococcus | WHO World Health Organisation

References

RECAP = Where a claim is followed by the RECAP, this means that this claim is endorsed by the RECAP board of experts.

OM Pharma Logo

The RECAP board is a panel of international experts in urological infections. The opinions presented within this educational material are those of the RECAP board and not those of OM Pharma. Members of the RECAP board include: Jose Tiran Saucedo (Mexico), Yvette León (Mexico), Gernot Bonkat (Switzerland), Kurt G. Naber (Germany), Florian ME. Wagenlehner (Germany), J C. Nickel (Canada), Flavia Rossi (Brazil), Enrique Ubertazzi (Argentina), Agnaldo L. da Silva Filho (Brazil), Tamara S. Perepanova (Russia), Bela Köves (Hungary) & Tommaso Cai (Italy).

Patient version : MED-HQ-UV-2100071 / HCP version : MED-HQ-UV-2100070
Date of preparation: December 2021